Disease reactivation after switching from natalizumab to daclizumab
| Autor: | Sergiu Groppa, Timo Uphaus, Christoph Oberwittler, Frauke Zipp, Stefan Bittner |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Daclizumab Neurology Anti-Inflammatory Agents Disease Antibodies Monoclonal Humanized Methylprednisolone 03 medical and health sciences Multiple Sclerosis Relapsing-Remitting 0302 clinical medicine Natalizumab Internal medicine medicine Humans Immunologic Factors Drug Substitution business.industry Multiple sclerosis medicine.disease Magnetic Resonance Imaging Discontinuation 030104 developmental biology Immunoglobulin G Immunology Alemtuzumab Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Neurology. 264:2491-2494 |
| ISSN: | 1432-1459 0340-5354 |
| Popis: | Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink